ACL — Australian Clinical Labs Cashflow Statement
0.000.00%
- AU$488.11m
- AU$756.99m
- AU$741.27m
Annual cashflow statement for Australian Clinical Labs, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.075 | 0.045 | 0.182 | 0.501 | 0.41 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 154 | 284 | 144 | 160 | 183 |
| Capital Expenditures | -9.51 | -21.3 | -6.93 | -6.5 | -8.41 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.43 | -50.8 | -5.25 | -0.742 | -0.484 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | -6.08 | -72 | -12.2 | -7.25 | -8.89 |
| Financing Cash Flow Items | -216 | -0.061 | 0 | -0.388 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -147 | -221 | -138 | -146 | -179 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.384 | -8.86 | -6.42 | 6.18 | -4.69 |